Duodenal-Jejunal Bypass Improves Non-alcoholic Fatty Liver Disease Independently of Weight Loss in Rodents with Diet-Induced Obesity.

Duodenal-Jejunal Bypass Improves Non-alcoholic Fatty Liver Disease Independently of Weight Loss in Rodents with Diet-Induced Obesity. Am J Physiol Gastrointest Liver Physiol. 2020 Aug 19;: Authors: Angelini G, Castagneto Gissey L, Casella Mariolo J, Caristo ME, Russo MF, Lembo E, Verrastro O, Stefanizzi G, Marini PL, Casella G, Bornstein SR, Rubino F, Mingrone G Abstract Nonalcoholic fatty-liver disease (NAFLD) is the most common cause of liver-related mortality. NAFLD is associated with obesity, hepatic fat accumulation and insulin-resistance, all of which contribute to its pathophysiology. Weight-loss is the main therapy for NAFLD and metabolic surgery is the most effective treatment for morbid obesity and its metabolic comorbidities. Although has been reported that Roux-en-Y gastric bypass can reverse NAFLD, it is unclear if such effects result from reduced weight, from a less calorie-intake or from the direct influence of surgery on mechanisms contributing to NAFLD. We aim to investigate whether gastrointestinal (GI) bypass surgery can induce direct effects on hepatic fat accumulation and insulin-resistance, independently of weight reduction. Twenty Wistar rats under a high-fat diet underwent duodenal-jejunal-bypass (DJB) or sham-operation and were pair-fed (PF) for 15 weeks after surgery to obtain a matched weight. Outcome measures include ectopic fat deposition, expression of genes and proteins involved in fat metabolism, insul...
Source: Am J Physiol Gastroi... - Category: Gastroenterology Authors: Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research